Avadomide-CC-122-DataSheet-生命科学试剂-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEAvadomideCat. No.: HY-100507CAS No.: 1015474-32-4Synonyms: CC 122分式: CHNO分量: 286.29作靶点: E1/E2/E3 Enzyme; Apoptosis作通路: Metabolic Enzyme/Protease; Apoptosis储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性

2、数据体外实验 DMSO : 33 mg/mL (115.27 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 3.4930 mL 17.4648 mL 34.9296 mL5 mM 0.6986 mL 3.4930 mL 6.9859 mL10 mM 0.3493 mL 1.7465 mL 3.4930 mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液，并请注意储备液的保存式和期限。BIOLOGICAL ACTIVITY物活性 Avadomid

3、e (CC 122)种新型的治疗DLBCL的药物，具有抗肿瘤和调节免疫活动的作。Avadomide (CC122) 可以结合CRBN，通过降解Aiolos和Ikaros可以模仿扰素信号，引发DLBCL的细胞凋亡。体外研究Avadomide inhibits proliferation and induces apoptosis in ABC and GCB DLBCL. In DLBCL cell lines,Avadomide-induced degradation or short hairpin RNA-mediated knockdown of Aiolos and Ikaros co

4、rrelates1/2 Master of Small Molecules 您边的抑制剂师www.MedChemEwith increased transcription of interferon (IFN)-stimulated genes independent of IFN-, -, and - productionand/or secretion and results in apoptosis in both activated B-cell (ABC) and germinal center B-cell DLBCL.1体内研究 Treatment of female CB-17

5、 SCID mice with Avadomide (CC122) at 3 or 30 mg/kg once daily significantlydecreased tumor growth in OCI-LY10 ABC-DLBCL (P = .028 and P .001, respectively) and WSU-DLCL2GCB-DLBCL derived xenograft models (P .01) compared with the vehicle control. In a separate study, weassessed the ability of Avadom

6、ide (CC122) to promote degradation of Ikaros and Aiolos in vivo. In the 21-day efficacy study of WSU-DLCL2 xenograft transplanted mice, tumors were excised 1, 6, or 24 hours postfinal dosing. Aiolos and Ikaros expression was interrogated through immunohistochemistry (IHC) and wasfound to be decrease

7、d 64% and 30%, respectively, compared with vehicle within 1 hour of treatment, with amaximal reduction of 94% and 69%, respectively, observed at 6 hours. Aiolos and Ikaros levels partiallyrecovered 24 hours postdosing with protein level within 20% and 34% of vehicle, respectively. The 24-hourpostdos

8、e Aiolos and Ikaros expression represents the trough compound level following multiple doses ofAvadomide (CC122). When the 1-hour time point is compared with the 24-hour postdose time point, there isa significant reduction in Aiolos but not Ikaros expression; however, at the 6-hour time point, botht

9、ranscription factors are significantly different from the 24-hour time point. Taken together, these data revealthat Avadomide (CC122) inhibited DLBCL tumor growth in vivo and that this activity was associated with thedegradation of Aiolos and Ikaros in both ABC- and GCB-DLBCL xenograft models.1PROTO

10、COLAnimal Female SCID mice (CB17/Icr-Prkdcscid, Charles River) were 8 weeks old, with body weights ranging fromAdministration 15.0 to 23.2 g, on day 1 of these studies. Each SCID mouse was injected subcutaneously in the right flankwith 5x106 OCI-LY10 cells (0.2 ml cell suspension). Tumors were calip

11、ered in two dimensions to monitorgrowth as their mean volume approached 100150 mm3. Fourteen days (WSU-DLCL2) or twenty-one days(OCI-LY10) after tumor cell implantation, mice were sorted into treatment groups (n=10/group). Tumors werecallipered twice weekly during the study. Avadomide (CC122) was su

12、spended in 0.5% carboxymethylcellulose: 0.25% Tween-80 in de-ionized water. Vehicle and Avadomide (CC122) were each administered viaoral gavage (p.o.) once daily for twenty-eight days (qd x28). 1MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Hagner, P.R.et al.CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.Blood.Aug6;126(6):779-89.McePdfHeightCa